| 000 | 01902 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517005446.0 | ||
| 264 | 0 | _c20150320 | |
| 008 | 201503s 0 0 eng d | ||
| 022 | _a1521-0111 | ||
| 024 | 7 |
_a10.1124/mol.114.094425 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPan, Yan | |
| 245 | 0 | 0 |
_aEnoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation. _h[electronic resource] |
| 260 |
_bMolecular pharmacology _c2015 |
||
| 300 |
_a378-90 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aEnoxaparin _xadministration & dosage |
| 650 | 0 | 4 | _aGefitinib |
| 650 | 0 | 4 | _aGene Expression Regulation, Neoplastic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred BALB C |
| 650 | 0 | 4 | _aMice, Nude |
| 650 | 0 | 4 |
_aPhosphorylation _xdrug effects |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-akt _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aQuinazolines _xadministration & dosage |
| 650 | 0 | 4 |
_aVimentin _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aXenograft Model Antitumor Assays _xmethods |
| 650 | 0 | 4 |
_arac GTP-Binding Proteins _xantagonists & inhibitors |
| 700 | 1 | _aLi, Xin | |
| 700 | 1 | _aDuan, Jianhui | |
| 700 | 1 | _aYuan, Lan | |
| 700 | 1 | _aFan, Shengjun | |
| 700 | 1 | _aFan, Jingpu | |
| 700 | 1 | _aXiaokaiti, Yilixiati | |
| 700 | 1 | _aYang, Haopeng | |
| 700 | 1 | _aWang, Yefan | |
| 700 | 1 | _aLi, Xuejun | |
| 773 | 0 |
_tMolecular pharmacology _gvol. 87 _gno. 3 _gp. 378-90 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1124/mol.114.094425 _zAvailable from publisher's website |
| 999 |
_c24440906 _d24440906 |
||